Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Dow
Boehringer Ingelheim
AstraZeneca
Medtronic

Last Updated: January 21, 2020

DrugPatentWatch Database Preview

BETAXOLOL HYDROCHLORIDE Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

When do Betaxolol Hydrochloride patents expire, and when can generic versions of Betaxolol Hydrochloride launch?

Betaxolol Hydrochloride is a drug marketed by Akorn, Apotex Inc, Medimetriks Pharms, Wockhardt, Epic Pharma, and Kvk Tech. and is included in six NDAs.

The generic ingredient in BETAXOLOL HYDROCHLORIDE is betaxolol hydrochloride. There are eleven drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the betaxolol hydrochloride profile page.

US ANDA Litigation and Generic Entry Outlook for Betaxolol Hydrochloride

  Start Trial

A generic version of BETAXOLOL HYDROCHLORIDE was approved as betaxolol hydrochloride by EPIC PHARMA on January 21st, 2020.

Drug patent expirations by year for BETAXOLOL HYDROCHLORIDE
Recent Clinical Trials for BETAXOLOL HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Ohio State UniversityPhase 1
University of OklahomaPhase 1
The University of Texas Health Science Center, HoustonPhase 1

See all BETAXOLOL HYDROCHLORIDE clinical trials

Pharmacology for BETAXOLOL HYDROCHLORIDE
Medical Subject Heading (MeSH) Categories for BETAXOLOL HYDROCHLORIDE
Synonyms for BETAXOLOL HYDROCHLORIDE
(+-)-1-(p-(2-(Cyclopropylmethoxy)ethyl)phenoxy)-3-(isopropylamino)-2-propanol hydrochloride
1-(4-(2-(Cyclopropylmethoxy)ethyl)phenoxy)-3-isopropylaminopropan-2-ol hydrochloride
1-(Isopropylamino)-3-(4-(2-(cyclopropylmethoxy)ethyl)phenoxy)propan-2-ol hydrochloride
1-(isopropylamino)-3-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]propan-2-ol hydrochloride
1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(isopropylamino)propan-2-ol hydrochloride
1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(propan-2-ylamino)-2-propanol hydrochloride
1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(propan-2-ylamino)propan-2-ol hydrochloride
1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(propan-2-ylamino)propan-2-ol;hydrochloride
1-[4-[2-(Cyclopropylmethoxy)ethyl]phenoxy]-3-isopropylamino-2-propanol hydrochloride
1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-isopropylamino-2-propanolhydrochloride
2-Propanol, 1-(4-(2-(cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino)-, hydrochloride, (+-)-
2-Propanol, 1-(4-(2-(cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino)-,hydrochloride
63659-18-7 (Parent)
63659-19-8
659X198
72424-72-7
A803574
AB2000314
AC-1412
AC1L331T
AC1Q3DQ4
AKOS015843993
alo 1401-02
AN-14973
API0001701
AS-18082
B 5683
B4474
BC227944
BCP02967
BCP0726000249
BCP9000394
Betaxolo Hydrochloride
Betaxolol (hydrochloride)
Betaxolol for peak identification, European Pharmacopoeia (EP) Reference Standard
Betaxolol HCL
Betaxolol hydrochloride (Betoptic)
Betaxolol hydrochloride (JP17/USP)
Betaxolol hydrochloride [USAN:USP:JAN]
Betaxolol hydrochloride [USAN]
Betaxolol hydrochloride, >98% (HPLC)
Betaxolol hydrochloride, European Pharmacopoeia (EP) Reference Standard
Betaxolol hydrochloride, United States Pharmacopeia (USP) Reference Standard
Betaxolol(hydrochloride)
Betoptic
Betoptic (TN)
Betoptic S
Betoptima
BG0105
CCG-101057
CCG-213473
CHDPSNLJFOQTRK-UHFFFAOYSA-N
CHEBI:643228
CHEMBL1691
CPD000058420
CS-2453
CTK8F0839
D00598
EINECS 264-384-3
EU-0100193
FT-0645228
HMS1569M05
HY-B0381A
I06-1154
Kerlon
Kerlone
Kerlone (TN)
Kerlong
KS-00001F73
Lokren
Lokren ,Kerlone ;Betoptic
LP00193
LS-122006
MCI-144
MFCD00242959
MLS000028464
MLS000758269
MLS000863279
MLS001148209
MLS001424199
MLS002222261
MolPort-003-666-823
NC00307
NCGC00093669-01
NCGC00093669-02
NCGC00260878-01
NSC-760048
NSC760048
Opera_ID_878
Pharmakon1600-01505512
Prestwick_779
Q-200714
S1827
SAM001247084
SCHEMBL42794
SL 75 212-10
SL 75.212-10
SL-75212
SL-75212-10
SMR000058420
SR-01000000108
SR-01000000108-2
SR-01000000108-4
SR-01000000108-9
SW196917-4
TC-071428
Tox21_500193
W0012
Paragraph IV (Patent) Challenges for BETAXOLOL HYDROCHLORIDE
Tradename Dosage Ingredient NDA Submissiondate
BETOPTIC SOLUTION/DROPS;OPHTHALMIC betaxolol hydrochloride 019270

US Patents and Regulatory Information for BETAXOLOL HYDROCHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Akorn BETAXOLOL HYDROCHLORIDE betaxolol hydrochloride SOLUTION/DROPS;OPHTHALMIC 075386-001 Jun 30, 2000 AT RX No No   Start Trial   Start Trial   Start Trial
Kvk Tech BETAXOLOL HYDROCHLORIDE betaxolol hydrochloride TABLET;ORAL 078962-001 Jun 27, 2008 AB RX No No   Start Trial   Start Trial   Start Trial
Wockhardt BETAXOLOL HYDROCHLORIDE betaxolol hydrochloride SOLUTION/DROPS;OPHTHALMIC 078694-001 Nov 16, 2009 AT RX No No   Start Trial   Start Trial   Start Trial
Kvk Tech BETAXOLOL HYDROCHLORIDE betaxolol hydrochloride TABLET;ORAL 078962-002 Jun 27, 2008 AB RX No No   Start Trial   Start Trial   Start Trial
Apotex Inc BETAXOLOL HYDROCHLORIDE betaxolol hydrochloride SOLUTION/DROPS;OPHTHALMIC 075446-001 Sep 28, 2000 DISCN No No   Start Trial   Start Trial   Start Trial
Medimetriks Pharms BETAXOLOL HYDROCHLORIDE betaxolol hydrochloride SOLUTION/DROPS;OPHTHALMIC 075630-001 Apr 12, 2001 AT RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
Baxter
Johnson and Johnson
AstraZeneca
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.